ArticleCVIR endovascular2025
Lipiodol marking for CT-guided radiofrequency ablation of adrenal aldosterone-producing adenomas: a case series.
Article in CVIR endovascular, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundTumor visualization during computed tomography (CT)-guided radiofrequency ablation (RFA) of adrenal adenomas is often limited by the small size of the lesion and needle-induced artifacts. These limitations can impair accurate needle placement and increase the risk of incomplete ablation. This report shows four adrenal RFA procedures in which iodized oil (Lipiodol®) marking enhanced lesion visibility. CASE PRESENTATION: CT imaging and adrenal venous sampling showed unilateral right aldosterone-producing adenomas measuring 10-20 mm in patients with primary aldosteronism. Contrast enhancement of the nodules was confirmed via CT angiography after microcatheter insertion into the adrenal artery. Transarterial embolization was performed utilizing a 1:1 mixture of Lipiodol and iohexol. In three cases, Lipiodol deposition within the adenomas was confirmed on CT immediately post-embolization and persisted on the following day. Despite needle-induced artifacts during RFA, nodule visibility significantly improved. RFA was completed without major complications, which resulted in the resolution of primary aldosteronism and hypertension. In one case, although Lipiodol marking was discontinued due to the extravasation from the adrenal artery branch, RFA was completed on the following day.
conclusionsCT-guided RFA with Lipiodol marking facilitated the effective treatment of aldosterone-producing adrenal adenomas in three patients by significantly enhancing lesion visibility. Adrenal arterial embolization should be addressed with caution to avoid damaging the small blood vessels of the adrenal gland.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.